MSA
RGNX icon

Mason Street Advisors’s Regenxbio RGNX Stock Holding History

Mason Street Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,160
Closed -$506K – 975
2020
Q4 		$506K Sell
11,160
-45
-0.4% -$1.57K 0.01% 1166
2020
Q3 		$308K Sell
11,205
-679
-6% -$22.1K 0.01% 1236
2020
Q2 		$438K Buy
11,884
+967
+9% +$36.1K 0.01% 1121
2020
Q1 		$353K Hold
10,917
– – 0.01% 1110
2019
Q4 		$447K Buy
10,917
+294
+3% +$11.6K 0.01% 1167
2019
Q3 		$378K Buy
10,623
+350
+3% +$14.2K 0.01% 1182
2019
Q2 		$528K Buy
10,273
+448
+5% +$22.4K 0.01% 1082
2019
Q1 		$563K Buy
9,825
+476
+5% +$23.6K 0.01% 1091
2018
Q4 		$392K Buy
9,349
+644
+7% +$37.8K 0.01% 1124
2018
Q3 		$657K Buy
8,705
+958
+12% +$69K 0.01% 1010
2018
Q2 		$556K Buy
+7,747
New +$370K 0.01% 1036

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mason Street Advisors's RGNX Position: Q1 2021 in Review

Mason Street Advisors sold out of Regenxbio (RGNX) in Q1 2021, closing a stake of 11,160 shares — an estimated $506K sold.

Mason Street Advisors first reported a position in RGNX in Q2 2018 and held it in 11 quarters. The position peaked at $657K in Q3 2018. 184 funds tracked by Wall St. Rank hold RGNX as of Q1 2021.

  • Mason Street Advisors reported no remaining Regenxbio position as of Q1 2021 after selling out during the quarter.
  • Mason Street Advisors sold 11,160 Regenxbio shares in Q1 2021, an estimated $506K.
  • Mason Street Advisors first reported a position in Regenxbio in Q2 2018 and held it in 11 quarters.
  • Mason Street Advisors's Regenxbio position peaked at $657K in Q3 2018.
  • 184 funds tracked by Wall St. Rank held Regenxbio as of Q1 2021.

Based on Mason Street Advisors's 13F filing for Q1 2021, filed 14 May 2021.